Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic breast cancer.~* Participants must have completed first line of metastatic chemotherapy and have achieved complete or partial response or disease stability for at least 6 months from the first confirmation of disease stabilization.~* No clinical sign of brain progression.~* At least one of the following 3 conditions: HER2 +++, Young age (\< 50 years), and/or estrogen receptor (ER)-/progesterone receptor (PgR)-~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.~* Life expectancy ≥3 months.~* Neutrophils ≥1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, hemoglobin ≥9 g/dL, lymphocytes ≥1 x 10\^9/L.~* Bilirubin level either normal or \<1.5 x ULN (upper limit of normal).~* AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤2.5 x ULN (≤5 x ULN if liver metastases are present).~* Serum creatine \<1.5 x ULN.~* Effective contraception if the risk of conception exists.~Exclusion Criteria:~* Concurrent chronic systemic immune therapy not indicated in the study protocol.~* Any investigational agent(s) within 4 weeks prior to entry.~* Participants that have completed 2nd, 3rd, or 4th line metastatic chemotherapy or participant in active chemotherapy treatment.~* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months.~* Acute or sub acute intestinal occlusion or history of inflammatory bowel disease.~* Known Grade 3 or Grade 4 allergic reaction to any of the components of the treatment.~* Known drug abuse/alcohol abuse.~* Legal incapacity or limited legal capacity.~* Medical or psychological condition which in the opinion of the investigator would not permit the participant to complete the study or sign meaningful informed consent.~* Women who are pregnant or breastfeeding.~* Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (participants with a previous malignancy but without evidence of disease for ≥5 years will be allowed to enter the trial).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): None
- Observational (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).